10.6084/m9.figshare.c.3660389_D2.v1
Daniela Massihnia
Daniela
Massihnia
Amir Avan
Amir
Avan
Niccola Funel
Niccola
Funel
Mina Maftouh
Mina
Maftouh
Anne van Krieken
Anne
van Krieken
Carlotta Granchi
Carlotta
Granchi
Rajiv Raktoe
Rajiv
Raktoe
Ugo Boggi
Ugo
Boggi
Babette Aicher
Babette
Aicher
Filippo Minutolo
Filippo
Minutolo
Antonio Russo
Antonio
Russo
Leticia Leon
Leticia
Leon
Godefridus Peters
Godefridus
Peters
Elisa Giovannetti
Elisa
Giovannetti
Additional file 1: Figure S1. of Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer
Springer Nature
2017
Pancreatic ductal adenocarcinoma
Akt
Synergism
Gemcitabine
2017-01-06 05:00:00
Presentation
https://springernature.figshare.com/articles/presentation/Additional_file_1_Figure_S1_of_Phospho-Akt_overexpression_is_prognostic_and_can_be_used_to_tailor_the_synergistic_interaction_of_Akt_inhibitors_with_gemcitabine_in_pancreatic_cancer/4529255
PFS curves according to phospho-Akt expression in radically-resected PDACs, showing that patients with high and âvery highâ phospho-Akt (right panel) had a significantly worse PFS. Figure S2. Growth inhibitory effects after MK-2206 exposure in LPC006 (72-hours). Figure S3. Growth inhibitory effects after 72 hours exposure to perifosine, gemcitabine or their combination at a fixed ratio based on IC50 values in CFPAC-1 and PANC-1 cells. On the X-axis the drug concentrations for the combination are referred to gemcitabine. Figure S4. Phospho-Akt (serine residue-473) expression, normalized to total Akt, after 4-hour exposure, as determined by ELISA. Figure S5. A Phospho-Akt (serine residue-473) expression, normalized to total Akt, after 24-hour exposure. B Phospho-Akt (threonine residue-308) expression, normalized to total Akt, after 24-hour exposure, as determined by ELISA. Figure S6. Expression of gemcitabine determinants in PANC-1 cells treated with perifosine, as determined by qRT-PCR. Dashed line, values in untreated samples. Figure S7. Wound-healing assay in CFPAC-1 and PANC-1 exposed to perifosine, gemcitabine or their combination (IC50 values, 24 hours). Figure S8. Wound-healing assay in LPC006 exposed to MK-2206, gemcitabine or to their combination (IC50 values, 24 hours). Figure S9. Annexin-V assay in LPC028 and LPC006. Figure S10: Modulation of caspase-3, caspase-6/-8/ and caspase-9 in CFPAC-1 and PANC-1, as determined by a specific fluorometric assay. Figure S11. Cell growth inhibition in LPC006 cells after 72-hour exposure to MK-2205, NVP-BEZ235 at IC50 values, together with DMSO or with the Glut1 inhibitor PGL13, at 30 ÎźM. Points, or Columns, mean values obtained from three independent experiments; bars, SEM. *Significantly different from controls. (PPTX 328 kb)